Viewing Study NCT00205192


Ignite Creation Date: 2025-12-24 @ 3:39 PM
Ignite Modification Date: 2025-12-31 @ 2:10 AM
Study NCT ID: NCT00205192
Status: COMPLETED
Last Update Posted: 2012-08-29
First Post: 2005-09-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Optimizing Cardiac Resynchronization
Sponsor: University of Wisconsin, Madison
Organization:

Study Overview

Official Title: Optimizing Cardiac Resynchronization
Status: COMPLETED
Status Verified Date: 2012-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Cardiac resynchronization therapy shows great promise as a method to improve ventricular function in heart failure due to dilated cardiomyopathy. It is applied to patients with class III and IV symptomatic heart failure on optimal therapy. Typical entry criteria in the trials testing resynchronization have used the electrocardiogram and a prolonged electrocardiogram (ECG) QRS interval as criteria for dyssynchrony. This is recognized to be quite limited as a tool for identifying patients. Several new echocardiographic methods for identifying dyssynchrony have been proposed. The purpose of this study is to systematically examine these multiple echocardiographic measurement techniques in three conditions:

1. in the patient's native rhythm simulated by changing the pacing system to atrial pacing only;
2. in conventional dual chamber pacing (DDD mode); and
3. during biventricular pacing. All patients entered into this study will already have had a biventricular pacemaker placed.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: